home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2863.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
50 lines
Document 2863
DOCN M94A2863
TI AZT monotherapy compared to AZT+DDC combined antiviral therapy and
AZT+DDC+NAC (100 patients each group).
DT 9412
AU Feregrino-Goyos M; Eid Lidt G; Gallegos Perez H; Alvarado DR; Mino LD;
Clinica ISI de Norteamerica, Mexico D.F., Mexico.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):208 (abstract no. PB0260). Unique
Identifier : AIDSLINE ICA10/94369712
AB OBJECTIVES: Comparison of the clinical response to three different
antiviral schematic in HIV patients with less than 500 CD4 (Stages II,
III, and IV del CDC). METHODS: During one year, 300 HIV patients with
less than 500 CD4 were studied. Group I 100 patients received daily 500
mg of AZT. Group II 100 patients received daily doses of 500 mg AZT +
2.25 mg of DDC. Group III 100 patients, received 500 mg AZT + 2.25 mg
DDC + 1500 mg of oral N-acetylcysteine. At the beginning and every 4
months of the study, Aids defining events as PNC, CMV, S.K.,
Cryptosporidiosis, etc., the age, CD4 count; p24 antigen levels,
Karnofsky index and mortality were evaluated. Statistic study was done
with parametric and non parametric tests. RESULTS: The age was 35, 37
and 36 respectively (p > 0.05), Karnofsky index 88, 79 and 78 (0 < 0.05)
CD4 were 247, 175 and 147 (p < 0.05), antigens p24 were 8.6, 9.7 and
8.13 (p > 0.05) and previous defining events of AIDS were 56, 62 and 62
(p < 0.05). At the end of the year 32% of Group I died, 11% of Group II
and 11% of Group III (p < 0.05). New defining+ events of AIDS manifested
themselves in 62, 32 and 23% of the cases (p < 0.05). Antigen p24
decreased only in Groups II and III but non significantly. Cells count
CD4 evolved each 4 months thus: in Group I, from 247.2, to 270.4, 236.2
and 180.8 (p < 0.05). In group II it augmented from 175.3 to 231, 286.3
and 293.8 (p < 0.05) and in the Group III it changed from 147.6 to
241.3, 303.3 and 356.6 (p < 0.05). The Karnofsky index was increasing
only in groups II and III. The most impressing results were to be
observed in patients with CD4 higher than 200. CONCLUSIONS: In our
patients, the combined therapy of AZT+DDC and AZT+DDC+NAC had better
effect on the evolution of the patients in comparison with the Group
treated only with AZT after one year with impressing results in
mortality rates and CD4 counts and Karnofsky index.
DE Acetylcysteine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Acquired
Immunodeficiency Syndrome/MORTALITY/PREVENTION & CONTROL Adult
AIDS-Related Opportunistic Infections/PREVENTION & CONTROL Comparative
Study Drug Therapy, Combination Human HIV Infections/*DRUG THERAPY
Karnofsky Performance Status Treatment Outcome
Zalcitabine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE
Zidovudine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE CLINICAL TRIAL
MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).